Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, Qatar Genome Program Partner to Develop Microarray for Arab Populations

NEW YORK – Thermo Fisher Scientific said on Monday that it has teamed up with the Qatar Genome Program (QGP) to develop a microarray for pan-Arab populations.

Under the agreement, the two organizations will develop a custom Axiom genotyping array based on whole-genome sequencing data from 19 Arab countries. The array will interrogate about 800,000 variants and will be used for research into various diseases including diabetes, cardiovascular disease, metabolic disease, autism, various genetic disorders, and cancer.

Financial and other terms of the partnership were not disclosed.

Thermo Fisher aims to make the array, which is intended to be an alternative to whole-genome sequencing, commercially available in late 2022.

"Our collaboration with Thermo Fisher will not only help us advance precision medicine in Qatar but also among people of Arab identity worldwide," Radja Badji, genome operations manager at QGP, said in a statement.

QGP, a member of the Qatar Foundation, and Thermo Fisher started collaborating in 2018 to develop another microarray, called Q-Chip, for the Qatari population. Under the new agreement, they will refine their algorithms and define variants for polygenic risk scores and pharmacogenomics.

The Scan

Monkeypox Meeting

As the World Health Organization gets ready to hold another monkeypox meeting, the US distributes vaccines and increases its testing capacity.

CRISPR's Softer Side

A homologous chromosome-templated repair approach to gene editing relies on versions of the Cas9 enzyme that cut a single DNA strand.

Pickled? No Problem

Researchers come up with an approach for extracting DNA from archived museum specimens. 

Nature Papers on Long Reads for Bacterial Genomes, Zebrafish Atlas, Hypothalamic Aging in Mammals

In Nature this week: near-finished microbial genomes without polishing, zebrafish functional annotation program, and more.